1. Home
  2. CERT vs CMPX Comparison

CERT vs CMPX Comparison

Compare CERT & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CERT

Certara Inc.

HOLD

Current Price

$6.39

Market Cap

978.7M

Sector

Technology

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$5.08

Market Cap

927.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CERT
CMPX
Founded
2008
2014
Country
United States
United States
Employees
1576
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
978.7M
927.5M
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
CERT
CMPX
Price
$6.39
$5.08
Analyst Decision
Buy
Strong Buy
Analyst Count
10
9
Target Price
$12.22
$14.43
AVG Volume (30 Days)
3.5M
1.8M
Earning Date
05-04-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
87.50
N/A
EPS
N/A
N/A
Revenue
$418,838,000.00
N/A
Revenue This Year
$4.26
N/A
Revenue Next Year
$5.40
$677.91
P/E Ratio
N/A
N/A
Revenue Growth
8.75
N/A
52 Week Low
$6.04
$1.33
52 Week High
$15.38
$6.88

Technical Indicators

Market Signals
Indicator
CERT
CMPX
Relative Strength Index (RSI) 37.09 34.85
Support Level $6.04 $4.86
Resistance Level $7.52 $5.86
Average True Range (ATR) 0.32 0.28
MACD 0.00 -0.03
Stochastic Oscillator 24.33 9.09

Price Performance

Historical Comparison
CERT
CMPX

About CERT Certara Inc.

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

Share on Social Networks: